A Director at NeoGenomics is Exercising Options

By Carrie Williams

Today it was reported that a Director at NeoGenomics (NEOResearch Report), Raymond Hipp, exercised options to sell 18,889 NEO shares at $6.49 a share, for a total transaction value of $357K.

In addition to Raymond Hipp, one other NEO executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on NeoGenomics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $76.48 million and quarterly net profit of $353K. In comparison, last year the company earned revenue of $67.79 million and had a net profit of $4.95 million. NEO’s market cap is $1.8B and the company has a P/E ratio of 319.67. Currently, NeoGenomics has an average volume of 747.7K.

Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $20.00, reflecting a 2.0% upside.

The insider sentiment on NeoGenomics has been neutral according to 32 insider trades in the past three months. This sentiment is slightly lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NeoGenomics, Inc. provides cancer diagnostics and pharma services. It operates through a network of cancer focused testing laboratories to provide genetic and molecular testing services.